SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00255658
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
This phase I trial is studying the side effects and best dose of temsirolimus when given
together with sorafenib in treating patients with unresectable or metastatic solid tumors.
Sorafenib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood
flow to the tumor. Giving sorafenib together with temsirolimus may kill more tumor cells.
NCT00255658 Unspecified Adult Solid Tumor, Protocol Specific
3 Interventions
Name: sorafenib tosylate
Description: Given orally
Type: Drug
Group Labels: 2 Treatment (sorafe Treatment (sorafenib tosylate, temsirolimus)
Name: temsirolimus
Description: Given IV
Type: Drug
Group Labels: 1 Treatment (sorafenib tosylate, temsirolimus)
Name: laboratory biomarker analysis
Description: Correlative studies
Type: Other
Group Labels: 1 Treatment (sorafenib tosylate, temsirolimus)
Primary Outcomes
Measure: Maximum tolerable dose (MTD) and recommended dose for phase II determined by dose-limiting toxicities (DLT) graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 Time: 4 weeks
Purpose: Treatment
Allocation: N/A
Single Group Assignment
There is one SNP
SNPs
To analyze the biologic effects of BAY 43-9006 and CCI-779 on downstream targets of the
P13K/Akt/mTOR and Raf signaling pathways. --- P13K ---
HPO Nodes